New USP Chapter on Method Transfer effective
Recommendation
Tuesday, 4 February 2025 9 .00 - 17.00 h
Establishment, Use and Maintenance of Analytical Reference Substances
In the Pharmacopeoial Forum (PF) from September/October 2009, a proposal for a General Chapter on method transfer was mentioned for the first time. Some time ago, a draft for a General Chapter <1224> was published in the PF. This chapter entitled "Transfer of Analytical Methods has now come into effet in the USP 35.
The method transfer is a documented process which establishes the evidence that a laboratory is qualified to use an analytical method which has been elaborated in another laboratory. Hereby the evidence must be brought that the laboratory has the knowledge and the ability to perform the analytical method as intended. The USP Chapter describes:
- the different types of transfers
- the required comparison tests
- Co-validation between two or more laboratories
- Re-validation as an alternatiive approach
- "Transfer Waiver" including justification where no method transfer is required
- Elements required for a successful method transfer
- The pre-approved transfer protocol
- The analytical method
- The transfer report
All these indications can be found in the General Chapter <1224> of USP 35.
Learn more about the new Chapter during the ECA Conference "Compliance Update: EP, USP, and JP - Update on New Monographs - Dealing with Divergent Compendial Methods", taking place from 21 - 22 June 2012 at the Corinthia Hotel in Prag, Czech Republic. Dr Chris Burgess, Member of the respective USP expert group who has elaborated the new chapter will present it.
Author:
Dr Günter Brendelberger
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
15.01.2025English Translation of Supplement II to the Japanese Pharmacopoeia (JP18) Published
08.01.2025EDQM publishes new FAQ on System Suitability Test (SST)
08.01.2025Pharmeuropa Chapter 2.1.7. Balances for Analytical Purposes published for Comments
08.01.2025How to Guarantee a Complete FDA Inspection Failure
11.12.2024Another FDA Warning Letter Based on Review of Records